Fibrocell Science, Inc. Inducted into Prestigious World Technology Network
October 25 2012 - 9:00AM
Business Wire
Fibrocell Science, Inc., an autologous cellular therapeutic
company focused on the development of innovative products for
aesthetic, medical and scientific applications, has been inducted
into the distinguished World Technology Network (WTN) as a result
of being named a finalist for the 2012 World Technology Award for
Biotechnology.
Comprised of more than 1,000 members leading innovative advances
in the fields of science and technology, the WTN presents its World
Technology Awards each year to outstanding innovators from each
sector within the technology arena.
Fibrocell Science, Inc. is at the forefront of cutting-edge
research into the potential medical and aesthetic use of
fibroblasts—skin cells responsible for the production of collagen
and contribute to the formation of connective tissue fibers. The
company recently launched LAVIV™ (azficel-T), the first and only
personalized cell treatment approved by the FDA to improve the
appearance of moderate to severe nasolabial folds or “smile line”
wrinkles in adults.
“We are honored Fibrocell Science, Inc. was selected as a
finalist for this notable award and has been inducted as a member
of the World Technology Network,” said David Pernock, Chairman and
CEO of Fibrocell Science, Inc. “This acknowledgement highlights the
innovative technology behind LAVIV, which isolates, purifies and
multiplies a patient’s own collagen producing fibroblast cells. Our
vision is to develop and bring the value of these unique fibroblast
cells to the medical and scientific community.”
The WTN evaluated 23 companies for the Biotechnology Award
including Genentech, GE, Complete Genomics and Harvard Bioscience.
Fibrocell was named a finalist along with four other companies.
About The World Technology Awards
The World Technology Awards are presented each year to the
outstanding innovators from each sector within the technology
arena, both as a way to honor those individuals and as a vetting
mechanism to determine the newest WTN members. The Awards are
announced each year in a gala ceremony at the close of the annual
World Technology Summit. The World Technology Summit is a global
gathering of the WTN membership as well as other delegates.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cellular
therapeutic company focused on the development of innovative
products for aesthetic, medical and scientific applications.
Fibrocell Science, Inc. is committed to advancing the scientific,
medical and commercial potential of autologous skin and tissue, as
well as its innovative cellular processing technology and
manufacturing excellence. For additional information, please visit
www.fibrocellscience.com.
About LAVIV™ (azficel-T)
LAVIV is indicated for use for the improvement of the appearance
of moderate to severe nasolabial fold wrinkles in adults. The
safety and efficacy of LAVIV for areas other than nasolabial folds
have not been established; nor has the efficacy of LAVIV beyond six
months been established. LAVIV is the first and only personalized
cell treatment approved by the FDA for aesthetic use.
LAVIV is now available in major metropolitan areas throughout
the U.S., exclusively through board-certified dermatologists and
plastic surgeons who have been trained by Fibrocell Science, Inc.
on the treatment process. A list of trained and certified
physicians is available at www.mylaviv.com and will be continually
updated as new physicians are trained and begin offering LAVIV in
their practice.
Important Safety Information About LAVIV™ (azficel-T)
LAVIV is made especially for you from your own skin cells. Using
someone else’s cells can cause a serious reaction. Do not let
anyone else use your LAVIV. Prior to injection, confirm with your
physician that your information on the LAVIV vial is correct. Your
healthcare provider will help you to decide whether you are a
candidate for LAVIV and may help you avoid some of the adverse
reactions from LAVIV. Before getting LAVIV, tell your healthcare
provider if you have any medical problems including allergic
reactions to any drugs or food, bleeding disorders or take
blood-thinning medicines like aspirin, ibuprofen, or COUMADIN®
(warfarin sodium), keloids or excessive scarring, skin cancer or
any malignancy, genetic disorders affecting your skin, immune
problems or take medicines that affect your immune system, or any
other illness or medical problem. Tell your healthcare provider if
you are allergic to the antibiotics amphotericin or gentamicin,
bovine materials (products made from cattle), or dimethyl sulfoxide
(DMSO). Do not use LAVIV if you have a skin infection on your face
because LAVIV treatment can make the infection worse.
The most common side effects of LAVIV are at the injection-site,
including redness, bruising, swelling, pain, bleeding, lumps,
irritation, and itchiness. In clinical trials with LAVIV, most
injection-site adverse reactions resolved within one week and most
required no treatment. There are additional adverse reactions that
occurred in less than 1% of patients following LAVIV treatment in
clinical trials. Talk to your healthcare provider about these
adverse reactions. For more information about LAVIV, please see
accompanying full Prescribing Information or visit
www.mylaviv.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50453754&lang=en